Frequently Asked Questions
Answers about regenerative medicine procedures, aftercare, pain control, and recovery — from Sean Mulvaney, MD.
Preparing for Your Procedure
1.How can I optimize conditions before my procedure?+
2.What if I am taking anticoagulation therapy or blood-thinning drugs?+
3.Are there medications that I should hold before my procedure, or that may interfere with my procedure?+
If you have any questions, please talk to Dr. Mulvaney about any decisions to hold a medication around the time of your procedure.
A literature review was conducted to identify which medications have compelling, evidence-based reasons to be held before regenerative medicine procedures, versus those commonly assumed to interfere but lacking supporting data. Several agents often held out of caution — statins, biologic DMARDs, and methotrexate — do not clear the evidentiary bar for a routine hold recommendation.
| Medication / Class | Recommendation | Basis / Level of Evidence |
|---|---|---|
| NSAIDs / other anti-inflammatories | HOLD | Well-established suppression of the early inflammatory phase required for platelet/growth-factor signaling; standard peri-procedural practice. |
| Aspirin (peri-PRP) | HOLD | Established interference with platelet activation central to PRP's mechanism of action. |
| Therapeutic anticoagulants | HOLD (case-by-case) | Established bleeding risk. Not all agents equal: LMWH (tinzaparin) also directly impairs MSC proliferation in vitro; fondaparinux appears MSC-neutral — a reasonable substitution if anticoagulation cannot be paused. |
| Fluoroquinolones | HOLD / AVOID | Direct tenocyte and collagen toxicity via MMP upregulation; ~4x increased tendinopathy risk and ~2.5x rupture risk, compounded by concurrent corticosteroid use. Rarely first-line antibiotics regardless. |
| Nicotine / smoking | HOLD (cessation) | Vasoconstriction, blunted VEGF-driven angiogenesis, and direct impairment of platelet growth-factor release — hits PRP's mechanism directly. 2–4 week cessation window best supported, though not RCT-defined. |
| Statins (HMG-CoA reductase inhibitors) | NO ROUTINE HOLD | Evidence is genuinely mixed: theoretical antiplatelet effect and a tendon MMP/tendinopathy signal exist, but counterbalanced by pro-angiogenic (EPC/eNOS) effects and known harms of stopping in cardiac-risk patients. No procedure-specific outcome data. Consider individualizing only for a patient with active tendinopathy or prior statin-associated tendon injury. |
| Biologic DMARDs (TNF inhibitors, IL-targeted agents) | NO ROUTINE HOLD | Orthopedic surgery literature shows discontinuation raises flare risk without clearly improving outcomes. The infection-risk rationale for holding applies far more to open/implant surgery than to a needle-based injection procedure. |
| Methotrexate | NO ROUTINE HOLD | In vitro data shows dose-dependent inhibition of MSC osteogenesis/chondrogenesis, but this is contradicted by stronger clinical evidence: an RCT in RA surgical patients found no difference in complications between continuing and suspending MTX, and continuing significantly reduced flare rates. Two systematic reviews concur. |
| Non-fluoroquinolone antibiotics | NO ROUTINE HOLD | No compelling data supporting withholding standard antibiotic classes before an orthobiologic procedure. |
Key Takeaway
Of the medications frequently questioned in this context, only four have compelling evidence supporting a hold: NSAIDs, aspirin/antiplatelet-anticoagulant agents, fluoroquinolones, and nicotine. Statins, biologic DMARDs, methotrexate, and non-fluoroquinolone antibiotics do not have evidence supporting routine discontinuation.
References
- Grennan DM, et al. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis. 2001;60:214-217.
- Effect of methotrexate in post-operative wound healing in rheumatoid patients undergoing foot and ankle surgery. ISRCTN86123456.
- Assessment and Comparison of the Efficacy of Methotrexate, Prednisolone, Adalimumab, and Tocilizumab on Multipotency of Mesenchymal Stem Cells. PMC7348038.
- Stopping Biologics Before Surgery May Raise Flare Risk in RA. Rheumatology Advisor, citing Arthritis Research & Therapy (2026).
- Perioperative Management of Biologic and Targeted Synthetic DMARDs in Orthopedic Surgery: Balancing Infection Risk and Disease Control. Microorganisms 2026;14:398.
- To stop or not to stop: what should we be doing with biologic DMARDs when patients undergo orthopaedic surgery? PMC8493102.
- Dose Tapering and Discontinuation of Biologic DMARDs in Axial Spondyloarthritis: A Narrative Review. Curr Rheumatol Rep. 2024. DOI: 10.1007/s11926-024-01137-w.
- Is Fluoroquinolone Exposure after Primary Tendon Repair Associated with Higher Rates of Reoperations? A Matched Cohort Study. Orthopedic Reviews, 2025.
- Short-Term Exposure to Ciprofloxacin Reduces Proteoglycan Loss in Tendon Explants. PMC9777606.
- Ciprofloxacin reduces tenocyte viability and proteoglycan synthesis in short-term explant cultures of equine tendon. PMC8411937.
- Positive Association Between Fluoroquinolone Exposure and Tendon Disorders: A Nationwide Population-Based Cohort Study in Taiwan. PMC8978711.
- Statin treatment increases the clinical risk of tendinopathy through matrix metalloproteinase release. Scientific Reports. 2019;9:17958.
- Effects of Statin Treatment on the Development of Tendinopathy: A Nationwide Population-Based Cohort Study. PMC10350772.
- Statins: bitter enemies of tendons or not? A systematic review of clinical evidence. PubMed PMID: 41182304.
- Tobert JA. Tendinopathy and Tendon Rupture Associated with Statins. PubMed PMID: 27490216.
- HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. PMC209365.
- Statins, HMG-CoA Reductase Inhibitors, Improve Neovascularization by Increasing the Expression Density of CXCR4 in Endothelial Progenitor Cells. PMC4550447.
- HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats. PubMed PMID: 15772528.
- Effects of Antithrombotic Drugs Fondaparinux and Tinzaparin on In Vitro Proliferation and Osteogenic and Chondrogenic Differentiation of Bone-Derived Mesenchymal Stem Cells. J Orthop Res. 2011;29:1327-1335.
- Why You Should Stop Smoking Before Your PRP Treatment. Ubie Doctor's Note, 2026.
- Orthopedic Surgery Complication Risk Associated with Smoking Cessation and Use of Nicotine Replacement Therapies: A Systematic Review. NCBI Bookshelf NBK595265.
- The influence of smoking and alcohol on bone healing: Systematic review and meta-analysis of non-pathological fractures. PMC8571530.
4.What supplements do I need to stop around the time of my procedure, and when should I stop them?+
Because Prolotherapy, PRP, and stem cell (BMAC) procedures work by triggering a controlled inflammatory healing response, anything that blunts inflammation or platelet function can interfere with the result. A number of common over-the-counter supplements have antiplatelet or anti-inflammatory effects and are generally held before and after your procedure.
General timing: Stop these approximately 1–2 weeks before your procedure and wait 2–4 weeks afterward before resuming, unless your provider gives you different instructions. (This window comes from general pharmacokinetics rather than a specific clinical trial, so your provider may adjust it for your situation.)
We make these recommendations to help optimize your procedure, not because any one of these supplements will stop it from working. Most will not eliminate the benefit of treatment — but they have the potential to somewhat blunt its effectiveness, so we ask patients to hold them during this window to give the healing response its best chance.
If you take any of these for a medical reason (for example, low-dose aspirin prescribed for heart or stroke prevention), do not stop without first checking with the prescribing physician.
Definitely Stop These
| Supplement | Why It Matters |
|---|---|
| Fish oil / omega-3 (EPA/DHA) | Reduces platelet clumping and dampens inflammation |
| Turmeric / curcumin | Inhibits the same inflammatory pathway (COX-2) the procedure relies on |
| Vitamin E (high dose) | Reduces platelet clumping |
| Concentrated garlic supplements | Reduces platelet clumping |
| Ginkgo biloba | Reduces platelet clumping |
| Ginger (supplement-strength) | Reduces platelet clumping and inflammation |
| NSAIDs (ibuprofen, naproxen, aspirin, etc.)* | Directly blocks the inflammatory response the procedure depends on |
*Not a supplement, but included here because it's asked about constantly and works the same way.
Worth Considering Stopping
| Supplement | Why It's Listed |
|---|---|
| Bromelain | Mild antiplatelet/anti-inflammatory effect |
| Green tea extract (concentrated) | Mild antiplatelet/anti-inflammatory effect |
| Resveratrol | Mild antiplatelet/anti-inflammatory effect |
| Boswellia | Mild anti-inflammatory effect |
| High-dose vitamin C | Effect on healing is debated — some evidence it supports collagen synthesis instead |
| Glucosamine / chondroitin | Commonly included out of caution, though the evidence for interference is thin |
Bottom Line
If you're not sure whether something you're taking belongs on this list, bring the bottle (or a photo of the label) to your visit and we'll sort it out together.
5.Does Dr. Mulvaney treat teenagers?+
6.Are you put to sleep or sedated for the procedures?+
7.What should I wear for this treatment?+
8.Can someone be in the room with me?+
9.How long does a treatment usually take?+
10.Can I drink alcohol the night before a procedure? How about after?+
11.Can I get a stellate ganglion block and a musculoskeletal treatment on the same day?+
Recovery & Aftercare
12.When can I shower after a procedure?+
13.Should I use ice or heat after my treatment?+
14.What can I use for pain control after a regenerative medicine procedure?+
15.How should I control the inflammation after a regenerative medicine procedure?+
16.Do I need a driver after my procedure?+
17.Will I be on crutches or in a sling after my procedure?+
18.How can I optimize my healing response?+
19.When will I follow up?+
20.What happens if I do not get the results I hoped for after a procedure?+
21.Can I go swimming or do water aerobics after a treatment?+
Returning to Movement
22.Will I do physical therapy after my procedure? If so, when?+
23.I'm almost feeling better — when can I return to my sport or activity?+
24.How do I start returning to running?+
Returning to running works best as a criteria-based, gradual progression rather than jumping straight back into your old routine. Before starting, you should be able to walk briskly for 30 minutes pain-free with normal gait mechanics, have full pain-free range of motion in the treated area, and tolerate light hopping or impact without pain or swelling.
A standard walk-run progression:
| Phase | Walk | Jog | Repeats | Days/Week |
|---|---|---|---|---|
| 1 | 4 min | 1 min | 3–6 | 2–3 |
| 2 | 3 min | 2 min | 3–6 | 2–3 |
| 3 | 2 min | 3 min | 3–6 | 2–3 |
| 4 | 1 min | 4 min | 3–6 | 2–3 |
| 5 | — | 30 min continuous | 1 | 3 |
- Do a 5–10 minute dynamic warm-up before each session, and take at least one rest day between running days.
- Run at a comfortable, easy effort — this isn't the phase for pace work.
- Only advance to the next phase once you can complete a full session pain-free, with no increased soreness or swelling afterward.
- Stop and back off if you get sharp pain, pain that worsens as you run, or pain significant enough to change your gait — talk to Dr. Mulvaney or your physical therapist before continuing.
- Once you complete Phase 5, increase weekly mileage by roughly 10% per week rather than jumping back to your prior volume all at once.
- Save speed work and hills for once you're back to 50–60% of your pre-injury weekly mileage; normal training can typically resume around 75–80%.
This is a general, evidence-informed framework — a physical therapist can tailor the pace of progression to your specific injury, running mechanics, and prior training level. Based on established graduated-return-to-running research, including Buist et al., Am J Sports Med. 2008;36:33-39, and Bredeweg et al., Br J Sports Med. 2012;46:865-870.
Payment
25.What form of payment does the ROSM Annapolis office take?+
26.Are regenerative treatments covered by most medical insurance companies?+
27.Can I use my FSA or HSA account to pay for regenerative medicine treatments?+
28.Do you offer CareCredit or any other form of payment plan?+
Still Have Questions?
Call our Annapolis office Monday through Friday, 8 AM to 5 PM.

